2024-514213-35-00CompletedPhase 1
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adults with Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists
Source: EU CTIS (euclinicaltrials.eu) · Last updated 1 Apr 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 30 Jul 2024
- Start date
- 20 Jan 2025
- Lead sponsor
- AstraZeneca AB
- Diseases
- Asthma
- EU CT number
- 2024-514213-35-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 24
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Velocity Clinical Research Germany GmbH | Ahrensburg | Germany | Completed |
| Studienpraxis Berlin-Brandenburg Cornelia Seelbinder Und Lennart Schaper GbR | Berlin | Germany | Completed |
| IKF Pneumologie GmbH & Co. KG | Frankfurt am Main | Germany | Completed |
| Velocity Clinical Research Germany GmbH | Luebeck | Germany | Completed |
| IKF Pneumologie GmbH & Co. KG | Mainz | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.